The AMR Action Fund, established in 2020 and backed by some of the world's largest pharmaceutical companies and other stakeholders, announced in a press release that Adaptive Phage Therapeutics (APT) and Venatorx Pharmaceuticals will be the first recipients of funding. While the amount invested in the companies has not been disclosed, the fund says it plans to invest more than $100 million in biotech companies this year, and $1 billion over the decade.

The AMR Action Fund is a groundbreaking VC fund that enables breakthroughs in the development of antibiotics, anti-fungals, and other antimicrobials. We invest in companies developing innovative treatments for priority drug-resistant pathogens and advocate for market reforms and policy solutions to change how society values these lifesaving drugs.